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Vijaykumar Nekkanti, Venkateswarlu Vabalaboina and Raviraj Pillai* 
Dr. Reddy’s Laboratories Limited, Hyderabad,  
India 
1. Introduction  
Advances in drug discovery technologies and combinatorial chemistry techniques have led 
to identification of a number of compounds with good therapeutic potential. However, 
because of their complex chemistry majority of these compounds have poor aqueous 
solubility resulting in reduced and variable bioavailability (Lipinski et al., 2002). The 
variability in systemic exposure observed often makes it difficult for dose delineation, 
results in fed and fast variability and in slower onset of action. These issues may lead to sub-
optimal dosing and concomitantly poor therapeutic response. For compounds with poor 
aqueous solubility that are ionizable, preparation of salts to improve solubility/dissolution 
rate is a commonly used approach that had limited success. From a product development 
standpoint, generally a crystalline salt is preferred due to potential physical and chemical 
stability issues associated with the amorphous form. Identification of a crystalline salt with 
adequate aqueous solubility requires screening various counter-ions and 
solvents/crystallization conditions and at times isolation of a crystalline material is difficult. 
In some instances the salt formed is extremely hygroscopic posing product development 
and manufacturing challenges (Elaine et al., 2008).  
Currently there are limited formulation approaches for compounds with poor aqueous 
solubility. The most commonly used approaches are micronisation and solid dispersions of 
the drug in water-soluble careers for filling into hard or soft gelatin capsules. Micronisation 
results in particles that are < 5 µm with a very small fraction that is in the sub-micron range. 
The decrease in particle size results in a modest increase in surface area that may not change 
the dissolution rate or saturation solubility to significantly impact bioavailability (Jens-Uwe 
et al., 2008).  
Solid dispersion compositions comprise of molecular dispersion of the drug in water 
soluble and lipid-based surface-active carriers that can emulsify upon contact with the 
dissolution medium. Formation of molecular dispersions (solid solution) provides a 
means of reducing the particle size of the compounds to nearly molecular levels (i.e., there 
are no visible particles). As the carrier dissolves, the compound is exposed to the 
dissolution media as fine particles that are amorphous, which can dissolve rapidly and 
concomitantly absorbed. These formulations are filled in soft or hard gelatin  
capsules. There are several products using this approach in the market, e.g., 
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625 mg / 5 mL. The drug nanosuspension reduced the fed and fast variability similar to 
Tricor®. The product in nanosuspension demonstrated that aqueous nanosuspension can be 
produced with adequate physical stability with acceptable shelf life using this technology. A 
list of products developed using nanoparticle technology (Ranjita Shegokar et al., 2010; Rajesh 
Dubey, 2006) currently available in the market is summarized in Table 1. 
 
Brand Generic 
Name 
Indication Drug 
Delivery 
Company 
Innovator Status 
Rapamune® Rapamycin, 
Sirolimus 
Immunosuppressant Elan 
Nanosystems
Wyeth Marketed 
Emend® Aprepitant Anti-emetic Elan 
Nanosystems
Merck & Co. Marketed 
Tricor® Fenofibrate Hypercholesterolemia Abbott 
Laboratories 
Abbott 
Laboratories 
Marketed 
Megace 
ES® 
Megestrol Anti-anorexic Elan 
Nanosystems
Par 
Pharmaceuticals 
Marketed 
Triglide® Fenofibrate Hypercholesterolemia IDD-P 
Skyepharma 
Sciele Pharma 
Inc. 
Marketed 
Avinza® Morphine 
Sulphate 
Phychostimulant Elan 
Nanosystems
King 
Pharmaceuticals 
Marketed 
Focalin Dexmethyl-
Phenidate 
HCl 
Attention Deficit 
Hyperactivity Disorder 
(ADHD). 
Elan 
Nanosystems
Novartis Marketed 
Ritalin Methyl 
Phenidate 
HCl 
CNS Stimulant Elan 
Nanosystems
Novartis Marketed 
Zanaflex 
Capusules
TM 
Tizanidine 
HCl 
Muscle Relaxant Elan 
Nanosystems
Acorda Marketed 
Table 1. Overview of nanoparticle technology based products  
3. Formulation theory 
The basic principle of micronisation and nanonisation is based on increase in surface area 
leading to enhancement in dissolution rate according to Noyes-Whitney equation (Muller et 
al., 2000). Poor aqueous solubility correlates with slower dissolution and decreasing particle 
size increases the surface area with concomitant increase in the dissolution rate. 
Dissolution kinetics is the primary driving force behind the improved pharmacokinetic 
properties of nanoparticle formulations of poorly water soluble compounds. Dissolution 
rate of a drug is a function of its particle size and intrinsic solubility. For drugs with poor 
aqueous solubility, surface area of the drug particles drives dissolution. As described by the 
Nernst-Brunner and Levich modification of Noyes-Whitney model the rate of drug 
dissolution is directly proportional to surface area; 
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 dx/dt = (A x D/δ) x (C - X/V)  (1) 
Where X is the amount of drug in solution, t is time, A is the effective surface area, D is the 
diffusion coefficient of the drug, δ is the effective diffusion boundary layer, C is the 
saturation solubility of the drug, and V is the volume of dissolution medium. 
Saturation solubility usually is a compound specific constant that depends on temperature. 
This understanding is true for regular particles that are above the micron range however, 
different for drug nanoparticles. This is because the dissolution pressure is a function of the 
curvature of the surface that means it is much stronger for a curved surface of nanoparticles. 
Below a particle size of approximately 2 μm, the dissolution pressure increases distinctly 
leading to an increase in the saturation solubility. In addition, the diffusional distance on the 
surface of drug nanoparticles is decreased, thus leading to an increased concentration 
gradient. The increase in surface area and concentration gradient lead to much more 
pronounced increase in dissolution velocity and saturation solubility compared to products 
containing micronized particles concomitantly resulting in improved bioavailability (Keck et 
al., 2006).  
Increased solubility near the particle surface results in enhanced concentration gradient 
between the surface and the bulk solution. The high concentration gradient according to 
Fick’s law must lead to an increased mass flux away from the particle surface (Dressman et 
al., 1998). As the particle diameter decreases, its surface area to volume ratio increases 
inversely, further leading to an increased dissolution rate. Under sink conditions in which 
the drug concentration in the surrounding medium approaches zero, rapid dissolution 
could theoretically occur.  
4. Production of drug nanoparticles 
There are several techniques used to produce drug nanoparticles. The existing technologies 
can be divided into two categories; ‘bottom up’ and ‘top down’. The bottom-up technologies 
involves controlled precipitation/crystallization by adding a suitable non-solvent. The top 
down technologies include milling or homogenization. However, combination techniques 
that involves pretreatment step followed by size reduction are also being used to produce 
nanoparticles with the desired size distribution.  
4.1 Bottom-up technologies (Precipitation methods) 
Precipitation has been applied for many years for preparation of fine particles, particularly 
in the development of photographic film, and lately for preparation of sub-micron (nano) 
particles for pharmaceutical applications (Otsuka et al., 1986; Illingworth, 1972). Examples 
for precipitation techniques are hydrosols developed by Sucker (Sandoz, presently Novartis) 
and Nanomorph developed by Soliqs/Abbott (Musliner, 1974; Sjostrom et al., 1993; 
Gassmann et al., 1994; List et al., 1988; Sucker et al., 1994).  
In this process, the drug is dissolved in a suitable solvent and the solution is subsequently 
added to a non-solvent. This results in high super saturation, rapid nucleation and the 
formation of many small nuclei. Upon solvent removal, the suspension is sterile filtered and 
lyophilized (Kipp et al. 2003). The mixing processes may vary considerably. Through careful 
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control of this addition process it is possible to obtain a particle with a narrow size 
distribution. In the case of Nanomorph, amorphous drug nanocrystals are produced to 
further enhance dissolution velocity and solubility (Muller et al., 2001a).  
Simple precipitation methods, however, have numerous limitations; it is very difficult to 
control nucleation and crystal growth to obtain a narrow size distribution. Often a 
metastable solid, usually amorphous, is formed which is converted to more stable crystalline 
forms (Violante et al., 1989; Bruno et al., 1992). Furthermore, non-aqueous solvents utilized 
in the precipitation process must be reduced to toxicologically acceptable levels in the end 
product and due to the fact that many poorly soluble drugs are sparingly soluble not only in 
aqueous but also in organic media. Considering these limitations, the “bottom up” 
techniques are not widely used for production of drug nanocrystals. Instead, “top down” 
technologies that include homogenization and milling techniques are more frequently used. 
4.2 Top-down technologies 
The two top down technology frequently used for producing drug nanoparticles include; 
a. High pressure homogenization  
b. Milling  
a. High pressure homogenization methods 
One of the disintegration method used for size reduction is high-pressure homogenization. 
The two-homogenization principles/homogenizer types used are; 
1. Microfluidisation (Microfluidics, Inc.) 
2. Piston-gap homogenizers (e.g. APV Gaulin, Avestin, etc.) 
b. Microfluidisation for production of drug nanoparticles  
Microfluidisation works on a jet stream principle where the suspension is accelerated and 
passes at a high velocity through specially designed interaction chambers. Frontal collision 
of fluid streams under high pressures (up to 1700 bar) inside the interaction chamber 
generates shear forces, particle collision, and cavitation forces necessary for particle size 
reduction. The Microfluidizer processor keeps a constant feed stream that gets processed by 
a fixed geometry which produces high shear and impact necessary to break down larger 
particles. This process yields smaller particles with narrow particle size distribution with 
repeatability and scalability.  
The interaction chamber’s exterior and interior is either made of stainless steel, poly-
crystalline diamond (PCD) or aluminum oxide. The poly-crystalline diamond chambers 
typically have a lifetime 3 - 4 times longer than the aluminum oxide ceramic chambers. 
Single slotted interaction chambers are used for lab-scale manufacturing and multi-slotted 
chambers for commercial scale. Multi-slotted chambers are comprised of multiple single 
slots in parallel for processing larger volumes of the products. There are two types of 
interaction chambers: Y chamber is useful for liquid-liquid emulsions and finds 
application in preparing liposomes while Z-chamber is typically used for cell disruption 
and nanodispersion. A schematic representation of mechanism of particle size reduction 
in high pressure homogenizers is shown in Fig. 1. The selection of correct chamber 
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depends upon the feed particle size, the application, and the amount of shear and impact 
required to carryout the operation. The Insoluble Drug Delivery – Particles (IDD-P™) 
technology developed by SkyePharma Canada Inc. use the Microfluidizer (Jens-Uwe et 
al., 2008).  
 
Fig. 1. Schematic representation of mechanism of particle size reduction in high pressure 
homogenizers 
4.2.1 Process parameters affecting particle size 
Studies on particle size reduction of a sparingly soluble drug (BCS class II) using the 
Microfluidizer (Model - Microfluidics M110-P) in our laboratory indicated that particle size 
reduction depends on various process parameters viz., number of homogenization cycles, 
homogenization pressure and, stabilizer concentration. At a constant homogenization 
pressure (30,000 psi) the value of mean particle size d50 decreased with increasing number 
of cycles from 5 to 60 (Fig. 2). Homogenization pressure has a significant effect on particle 
size distribution as shown in Fig. 3. At high homogenization pressure (30,000 psi) particle 
size reduction was significantly higher than at low homogenization pressure (10,000 psi) 
after 60 homogenization cycles. Surfactant concentration also plays an important role in 
particle size reduction through particle stabilization by forming a thin layer around the 
newly formed surface as evident based on the observation that at constant homogenization 
www.intechopen.com
 
Drug Nanoparticles – An Overview 
 
117 
pressure and homogenization cycles, particle size reduced with increase in surfactant 
concentration from 10 mg/mL to 12 mg/mL (Fig. 4).  
 
 
Fig. 2. Effect of number of cycles on mean particle size at constant homogenization pressure  
 
 
Fig. 3. Effect of homogenization pressure on particle size distribution  
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4.4 Milling methods  
Conventional milling and precipitation processes generally result in particles much greater 
than 1 μm. Milling techniques were later refined to enable milling of solid drug particles to 
sub-micron range. Ball mills are already known from the first half of the 20th century for the 
production of fine suspensions. In this method, the suspension comprising of drug and 
stabilizers along with milling media are charged into the grinding chamber. The reduction 
of particle size occurs because of the shear forces generated due to impaction of milling 
media. In contrast to high pressure homogenization, this is a low energy technique. Smaller 
or larger beads can be used as milling or attrition media. The milling media comprise of 
ceramics (cerium or yttrium stabilized zirconium dioxide), stainless steel or highly cross 
linked polystyrene resin-coated beads. Potential for erosion of the milling media during the 
milling process resulting in product contamination is one of the drawbacks of this 
technology. To overcome this issue, the milling media are often coated (Merisko-Liversidge 
et al., 2003). Another problem with milling process is the adherence of product to the inner 
surface of the mill (consisting mainly of the surface of milling media and the inner surface of 
milling chamber). There are two basic milling principles - either the milling medium is 
moved by an agitator or the complete container is moved in a complex direction leading to 
movement of the milling media to generate the shear forces required to fracture the drug 
crystals. The milling time depends on many factors such as solid content, surfactant 
concentration, hardness, suspension viscosity, temperature, energy input and, size of the 
milling media. The milling time may vary from minutes to hours or days depending on the 
particle size desired (Jens-Uwe et al., 2008). 
In the bead milling process used for production of drug nanosuspension, the drug 
suspension is passed through a milling chamber containing milling media ranging from 0.2 
to 3 mm. These media may be composed of glass, zirconium salts, ceramics, plastics (e.g., 
cross-linked polystyrene) or special polymers such as hard polystyrene derivatives. The 
drug concentration in the suspension may range from 5 – 40% w/v. Stabilizers such as 
polymers and/or surfactants are used to aid the dispersion of particles. To be effective the 
stabilizers must be capable of wetting the drug particles and providing steric and ionic 
barrier. In the absence of appropriate stabilizers, the high surface energy of the nanometer-
sized particles would lead to agglomeration or aggregation of drug crystals. The 
concentration of polymeric stabilizers can range from 1 – 10% w/v and the concentration of 
surfactants is generally < 1 % w/v. If required other excipients such as buffers, salts and 
diluents like sugar can be added to the dispersion to enhance stability and aid further 
processing (Keck et al., 2006).  
The milling chamber has a rotor fitted with disks that can be accelerated at the desired 
speed (500 – 5000 RPM). The rotation of the disk accelerates the milling media radially. The 
product flows axially through the milling chamber where the shear forces generated and/or 
forces generated during impaction of the milling media with the drug provides the energy 
input to fracture the drug crystals into nanometer-sized particles. The temperature inside 
the milling chamber is controlled by circulating coolant through the outer jacket. The 
process can be performed either in a batch mode or in a recirculation mode. The milled 
product is subsequently separated from the milling media using a separation system. A 
schematic of the bead milling process is shown in Fig. 5. 
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Fig. 5. Schematic of wet bead milling process used for production of drug nanoparticles 
Scaling up the bead milling process is relatively easy and convenient because the process 
variables are scale independent. The batch size can be increased above the void volume 
(volume in between the hexagonal packaging of the beads) using the mill in a recirculation 
mode. The suspension is contained in the product container and is continuously pumped 
through the mill in a circular motion. This increases the batch size with concomitant increase 
in the milling time because the required exposure time of the drug particles per unit mass to 
the milling material remains unchanged. 
Surfactants or stabilizers have to be added to ensure physical stability of the 
nanosuspensions. In the manufacturing process the drug substance is dispersed by high 
speed stirring or homogenizer in a surfactant/ stabilizer solution to yield a macro 
suspension. The choice of surfactants and stabilizers depends not only on the physical 
principles (electrostatic versus steric stabilization) and the route of administration. In 
general, steric stabilization is recommended because it is less susceptible to electrolytes in 
the gut or blood. Electrolytes if added can reduce the zeta potential and subsequently impair 
the physical stability, especially of ionic surfactants. In many cases an optimal approach is 
the combination of a steric stabilizer with an ionic surfactant, i.e, a combination of steric and 
electrostatic stabilization. There is a wide variety of bead mills available in the market, 
ranging from laboratory-scale to industrial-scale volumes. The ability for large-scale 
production is an essential prerequisite for introduction of product into market. In general, 
bead milling offers a convenient process for production of drug nanoparticle at high 
concentrations necessary for solid dosage form processing with ease of scale-up for 
commercial manufacturing.  
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5. Process optimization for the production of drug nanoparticles 
Experimental design has been applied widely to formulation development, and is useful in 
process optimization and process validation (Fisher RA, 1926). A manufacturing process 
optimized using design of experiments (DOE) should result in a robust process amenable 
for seamless scale-up and validation (Dhananjay et al, 2010; Nekkanti et al, 2009a). The 
process variables in media milling can be optimized using design of experiments (DOE) to 
understand the effect on particle size, milling time and percentage yield (Nekkanti, et al., 
2010). Though a number of statistical designs are reported, a face centered centre composite 
design (CCD) is often used because it provides information on direct effects, pair wise 
interaction effects and curvilinear variable effect (Billon et al., 2000; Vaithiyalingam & Khan, 
2002; Tagne et al., 2006). For example, a design matrix prepared based on 3 variable factors 
at three levels (-1, 0, +1) to compute the design using statistical software program Design 
Expert (version No. 7.3.1) is summarized in Table 2. 
 
S. No Process Parameters 
Level 
Low (-1) Center (0) High (+1) 
1 Disk Speed (RPM) 2000 2350 2750 
2 Pump Speed (RPM) 40 50 60 
3 
Bead Volume in Milling 
Chamber (%) 
60 70 80 
Table 2. Process variables (factors) and levels 
A stepwise regression can be used to generate quadratic equations for each response 
variable. Analysis of variance (ANOVA) and regression is used to evaluate the significant 
effects and model building for each response variable. Each response is then fitted to a 
second-order polynomial model and, the regression coefficients for each term in the model 
can be estimated along with R2 and adjusted R2 of regression model to understand how 
these parameters effect the critical product attributes either through non-linear, quadratic or 
interaction effects.  
The interaction effect of pump and disc speed on milling time is shown in Fig. 6. The plot 
indicates that at lower disk speed the milling time (to achieve the desired particle size) 
increases. This may be attributed to the fact that at low disk speed the shear forces generated 
by accelerating beads may not be sufficient to fracture the drug crystals into smaller 
particles. The milling efficiency was high when the disk and pump were run at moderate 
speeds.  
The interaction effect of pump speed and bead volume on particle size is shown in Fig. 7. 
The plot indicates that increase in pump speed and bead volume resulted in larger particles 
where as, their interaction resulted in a decrease in particle size. Both pump speed and bead 
volume have an effect on particle size with bead volume having a significant impact in 
controlling the drug particle size due to increased probability of impaction.  
The interaction effect of disk speed and bead volume on yield is shown in Fig. 8. The plot 
indicates that the process yields obtained was significantly affected by disk speed and bead 
volume. At lower disk speed and higher bead volume there was a decrease in yield; this 
may be attributed to loss in the milling chamber due to sticking.  
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Fig. 6. Effect of disk and pump speeds on milling time 
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Fig. 7. Effect of pump speed and bead volume on particle size 
The robustness of the model used can be validated based on confirmatory trials to ascertain 
difference between predicted and experimental values. The use of DOE for process 
optimization will result in a robust scalable manufacturing process with design space 
established for critical process parameters that can balance milling time, particles size and 
yield. 
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7.1.1 Spectroscopy  
As nanosuspensions usually comprise of submicron particles, the appropriate method used 
to evaluate particle size distribution is photon correlation spectroscopy (PCS). In PCS or 
dynamic light scattering analyses scattered laser light from particles diffusing in a low 
viscosity dispersion medium (e.g. water). PCS analyze the fluctuation in velocity of the 
scattered light rather than the total intensity of the scattered light. The detected intensity 
signals (photons) are used to measure the correlation function. The diffusion coefficient D of 
the particles is obtained from the decay of this correlation function. Applying Stokes-
Einstein equation, the mean particle size (called z-average) can be calculated. In addition, a 
polydispersity index (PI) is obtained as a measure for the width of the distribution. The PI 
value is 0 in case particles are monodisperse. Incase of narrow distribution, the PI values 
vary between 0.10 – 0.20, values of 0.5 and higher indicate a very broad distribution 
(polydispersity). From the values of z-average and PI, even small increases in size of drug 
nanoparticles can be evaluated. The extent of increase in particle size upon storage is a 
measure of instability. Therefore, PCS is considered as a sensitive instrument to detect 
instabilities during long-term storage (Kerker, 1969). 
7.1.2 Laser Diffraction 
Laser Diffractometry (LD) developed around 1980 is a very fast and used routinely in 
many laboratories. The instrument is also used for quantifying the amount of 
microparticles present, which is not possible using PCS. LD analyses the Fraunhofer 
diffraction patterns generated by particles in a laser beam. The first instruments were 
based on the Fraunhofer theory which is applicable for particle sizes 10 times larger than 
the wavelength of the light used for generating the diffraction pattern. For particle less 
than 6.3 μm (in case of using a helium neon laser, wavelength 632.8 nm) in size, the Mie 
theory is used to obtain the correct particle size distribution. The Mie theory requires 
knowledge of the actual refractive index of particles and their imaginary refractive index 
(absorbance of the light by the particles). Unfortunately, for most of pharmaceutical solids 
the refractive index is unknown. However, laser diffractometry is frequently used as a 
preferred characterization method for nanosuspensions because of its “simplicity” (Zhang 
et al., 1992; Calvo et al., 1996).  
7.2 Microscopy 
Microscopy based techniques can be used to study a wide range of materials with a broad 
distribution of particle sizes, ranging from nanometer to millimeter scale. Instruments used 
for microscopy based techniques include optical light microscopes, scanning electron 
microscopes (SEM) transmission electron microscopes (TEM) and atomic force microscopes 
(AFM). The choice of instrument for evaluation is determined by the size range of the 
particles being studied, magnification, and resolution. However, the cost of analysis is also 
observed to increase as the size of the particles decreases due to requirements for higher 
magnification, improved resolution, greater reliability and, reproducibility. The cost of size 
analysis also depends upon the system being studied, as it dictates the technique used for 
specimen preparation and image analysis. Optical microscopes tend to be more affordable 
and comparatively easier to operate and maintain than electron microscopes but have 
limited magnification and resolution (Molpeceres et al., 2000; Cavalli et al., 1997).  
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The surface morphology of ‘as-is’ drug and spray dried nanoparticles for a sparingly soluble 
drug, Candesartan cilexetil, examined using scanning electron microscope (Hitachi S-520 
SEM, Tokyo, Japan) is shown in Fig. 9. The scanning electron micrographs of “as-is” drug 
and drug nanoparticles as shown in these Figures illustrate the recrystallization of water-
soluble carrier around the drug creating a highly hydrophilic environment preventing 
particle interaction and aggregation. 
 
 
  
 
 
 
Fig. 9. SEM micrographs of “as-is” drug (left); spray-dried drug nanoparticles (right). 
7.3 Solid-state properties  
7.3.1 Differential Scanning Calorimetry (DSC) 
Differential scanning calorimetry (DSC) is used to determine the crystallinity of drug 
nanoparticles by measuring its glass transition temperature, melting point and their 
associated enthalpies. This method along with X-ray powder diffraction (XRPD) described 
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below is used to determine the extent to which multiple phases exist in the interior and their 
interaction following the milling process. 
7.3.2 X-ray powder diffraction (XRPD) 
X-ray powder diffraction (XRD) is a rapid analytical technique primarily used for phase 
identification of a crystalline material and can provide information on unit cell dimensions. 
X-ray diffraction is based on constructive interference of monochromatic X-rays and a 
crystalline sample. These X-rays generated by a cathode ray tube are filtered to produce 
monochromatic radiation, collimated to concentrate, and directed toward the sample. The 
interference obtained is evaluated using Bragg’s Law to determine various characteristics of 
the crystal or polycrystalline material (Hunter et al., 1981).  
7.4 Saturation solubility 
Saturation solubility evaluations to ascertain drug nanoparticles are usually carried out in 
buffer media at different pH conditions using a shake flask method. In this method excess 
amount (100 mg/mL) of drug (“as-is” and dried suspension containing microparticles or 
nanoparticles) is added to 25 mL of buffer medium maintained at 37°C and shaken for a 
period up to 24 hours. The samples are filtered using 0.10 µm pore size Millex-VV PDVF 
filters (Millipore Corporation, USA) prior to analysis and concentrations determined using 
an HPLC method. The results from saturation solubility for “as-is”, micronized and spray 
dried nanoparticles of Candesartan cilexetil used as a model drug is summarized in Table 3 
to demonstrate the impact of particle size on saturation solubility.  
 
Solvents 
Solubility (mg/mL) 
“as-is” drug* Micronized drug* 
Spray dried drug 
nanoparticles 
0.1 N HCl 0.011 0.016 0.134 
Acetate buffer  
pH 4.5 
0.001 0.014 0.106 
Phosphate buffer 
pH 6.8 
0.001 0.012 0.105 
Water 0.000 0.001 0.073 
*Solubility was tested in respective solvents containing surfactant and Stabilizer.  
Table 3. Saturation solubility of “as-is”, micronized and nanoparticles of Candesartan 
cilexetil 
The saturation solubility of Candesartan cilexetil nanoparticles is significantly higher than 
jet-milled particles and “as-is” drug at all pH conditions. These results clearly demonstrate 
that reduction in particle size to sub-micron or nanometer range affects saturation solubility 
resulting in enhancement of dissolution rate. 
The effect of particle size of Candesartan cilexetil following oral administration in male 
Wistar is shown in Fig. 10. As seen there is a significant enhancement in the rate and 
extent of drug absorption for nanosuspension. The rate and extent of drug absorption 
www.intechopen.com
 
The Delivery of Nanoparticles 
 
128 
showed a 2.5-fold increase in the area under the plasma concentration - time curve (AUC0-
t) and a 1.7-fold increase in the maximum plasma concentration (Cmax) and, significant 
reduction in the time required (1.81 hours as compared to 1.06 hours) to reach maximum 
plasma concentration (Tmax) when compared to the micronized suspension (Nekkanti et 
al., 2009b). 
 
Fig. 10. Plasma concentration–time profiles following oral administration of micronized 
suspension and drug nanosuspension to male Wister rats 
8. Conclusion  
Enhancing solubility and dissolution rate of poorly soluble compounds correlates with 
improved pharmacokinetic (PK) profile. The approach herein can be extended to other BCS 
class II compounds where absorption is either solubility and/or dissolution limited. The 
manufacturing process used is relatively simple and scalable indicating general applicability 
of the approach to develop oral dosage forms of poorly soluble drugs. The enhanced 
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25 reputable chapters were framed in this book and there were alienated into four altered sections; Toxic
Nanoparticles, Drug Nanoparticles, Biological Activities and Nano-Technology.
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